Shots:
- CRISPR & Sirius have partnered to co-develop & co-market SRSD107, with CRISPR having the option to nominate ~2 siRNA targets, fund related research, & retain opt-in rights for clinical development & marketing
- As per the deal, Sirius will receive $25M cash & $70M in equity upfront, with both companies jointly developing SRSD107 under a 50-50 cost & profit-sharing structure; CRISPR to lead US marketing, while Sirius will handle Greater China
- SRSD107 (Factor XI inhibitor) is currently being evaluated in a P-II trial for the prevention of VTE while 2 P-I trials showed over 93% reductions in FXI levels & activity, along with a twofold increase in aPTT, with effects sustained for 6mos.; data was presented at ACC 2025 & ASH 2024
Ref: CRISPR Therapeutics|Â Image:Â CRISPR & Sirius|Â Press Release
Related News:- Regeneron to Acquire 23andMe Assets for $256M
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
